Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Jakavi (Ruxolitinib)
Jakavi (Ruxolitinib) is a medication specifically indicated for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms associated with primary myelofibrosis in adult patients.
Uses of Jakavi (Ruxolitinib)
Jakavi (Ruxolitinib) is used for:
Treating disease-related symptoms and reducing spleen size in adult patients with primary myelofibrosis.
Benefits of Jakavi (Ruxolitinib)
Alleviates symptoms such as abdominal discomfort, early satiety, and fatigue associated with primary myelofibrosis.
Reduces spleen size, improving overall quality of life for patients.
Offers targeted therapy that addresses the underlying pathology of myelofibrosis, potentially delaying disease progression.
Mechanism of Action of Jakavi (Ruxolitinib)
Jakavi (Ruxolitinib) works by inhibiting Janus kinase (JAK) signaling pathways, which are involved in the pathogenesis of myelofibrosis. By blocking these pathways, Jakavi reduces inflammation, controls abnormal cell proliferation, and mitigates symptoms associated with the disease.